Retrophin gets FDA nod to begin Phase I trial of phosphopantothenate replacement therapy

The US Food and Drug Administration (FDA) has reviewed Retrophin's investigational new drug (IND) application for RE-024, a new phosphopantothenate replacement therapy, and granted clearance to begin a Phase I clinical trial in healthy adult voluntee…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news